USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
LIFEPHARMS, INC.
Address:
143 Shaw Street
New London, CT 06320-
Phone:
N/A
URL:
N/A
EIN:
61369101
DUNS:
172904067
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
Yes
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $2,189,708.00 7
SBIR Phase II $904,482.00 1

Award List:

POTENTIAL ANTICANCER AGENTS FROM BASIDIOMYCETES

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Esteban E. Mena
Abstract:
LifePharms, Inc. has established a collection of >12,000 unique species of basidiomycetes/ascomycetes, and the Natural Products Laboratory of Research Triangle Institute has a long and successful history of isolating potent antitumor agents from natural sources. By teaming our respective… More

Discovery of cell cycle inhibitors from natural products

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$904,482.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The need for new and effective chemotherapeutic agents that selectively target cancer cells and thus, would have a much higher therapeutic index is urgent. Most chemotherapeutic agents damage normal dividing cells which accounts for the majority of the side… More

Discovery of novel antibacterials from a mushroom natural product library

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$378,012.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The dramatic increase in the prevalence of antibiotic resistance among important hospital- and community-acquired bacterial pathogens poses a serious threat to our ability to effectively treat infectious diseases. This growing problem necessitates the… More

Discovery of novel agents against M. tuberculosis.

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Despite the fact that tuberculosis is a major public global health problem, there have been no drugs developed for it since the 1960s. In 2006 tuberculosis caused 1.7 million deaths annually with approximately 8 million new cases emerging annually. Tuberculosis… More

Nucleoside hydrolase Inhibitors from natural products for Leishmania

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$211,698.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Our goal is to identify novel drugs for the treatment and chemoprophylaxis of Leishmania by blocking nucleoside hydrolase (NH) activity of this parasite. Leishmaniasis is a zoonosis and affects 12 million people in 88 c ountries, of which 72 are considered… More

Novel Antibacterial Scaffold from Natural Products

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$600,000.00
Agency:
HHS
Principal Investigator:
Esteban E. Mena – 860-447-8583
Abstract:
DESCRIPTION (provided by applicant): Despite the rise of bacterial resistance to antibiotics, the development of new antibiotics is on the decline. Methicillin-resistant Staphococcal aureus infections (MRSA) in the United States has been increasing, causing 19,000 deaths per year in the United… More

Novel antifungals for Immunocompromised/HIV patients.

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$300,000.00
Agency:
HHS
Principal Investigator:
Esteban E. Mena – 860-447-8583
Abstract:
DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV- infected patients. At present, there are only three classes of antifungal agents that are suitable for the treatment of AIDS-relatedfungal infections, but these medications are… More

Hsp90 inhibitors to combat antifungal drug resistance.

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$299,998.00
Agency:
HHS
Principal Investigator:
Esteban E. Mena – 860-447-8583
Abstract:
DESCRIPTION (provided by applicant): Fungal infections continue to be a major cause of morbidity and mortality among HIV-infected patients. Many of the emerging fungal pathogens that are resistant to the three classes of antifungal agents for AID-s-relatedinfections are becoming more common and are… More